Press "Enter" to skip to content

Bioaffinity Technologies With UV Detectable Lung Cancer Cell Technology Files S-1 With SEC

Bioaffinity Technologies files Form S-1, Registration for Securities / Prospectus, with SEC on September20, 2023. The company identifies Cypath Lung (trademarked) technology as using “a synthetic porphyrin called meso-tetra (4-carboxyphenyl) porphyrin (“TCPP”). Porphyrins are biological pigments that, when exposed to ultraviolet light at certain wavelengths, can result in the cell fluorescing a red or purplish…

This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.